Ipamorelin 10 mg

Ipamorelin is a synthetically engineered pentapeptide classified as a selective growth hormone secretagogue. It is designed to activate the ghrelin (GHS-R1a) receptor, leading to a targeted and efficient stimulation of endogenous growth hormone (GH) release and subsequent insulin-like growth factor-1 (IGF-1) production.

Unlike earlier growth hormone–releasing peptides, Ipamorelin demonstrates a high degree of selectivity for GH secretion while exerting minimal influence on other endocrine axes, including adrenocorticotropic hormone (ACTH) and cortisol. This selective signaling profile makes it a valuable research compound in studies related to metabolism, tissue repair, gastrointestinal motility, and pain modulation.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Ipamorelin binds selectively to the growth hormone secretagogue receptor (GHSR-1a) without significantly affecting cortisol, prolactin, or ACTH levels, distinguishing it from earlier GHSs. Research has investigated its role in GH pulse amplification, IGF-1 modulation, and lean mass preservation. Its selectivity profile has made it a preferred compound for studying GHSR pharmacology and age-related growth hormone decline. Combination research with CJC-1295 has explored synergistic GH pulse amplification effects (Raun et al., 1998 — European Journal of Endocrinology).

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling. Store at -20°C. See also: CJC-1295 No DAC 10 mg, Sermorelin 5 mg, CJC-1295 (No DAC) + Ipamorelin (10 mg) (Blend)